Ochratoxin A

Synonyms: 赭曲霉毒素 A; Phe-​OTA
Ochratoxin A (Phe-OTA) 是一种口服有效的、可穿透血脑屏障的食源性真菌毒素,是曲霉属 (Aspergillus) 和青霉属 (Penicillium) 真菌的次生代谢产物,属于 2B 类致癌物,其通过诱导氧化应激、抑制线粒体呼吸、造成氧化性 DNA 损伤、破坏 PPAR-γ-CD36 轴、诱导免疫抑制、介导线粒体依赖性凋亡 (apoptosis)、抑制谷氨酸吸收、引发脱髓鞘病变与神经炎症、导致 DNA 低甲基化及抑制细胞增殖等途径,可诱发肾毒性、肝毒性、免疫毒性、神经毒性,并具有致突变性、致畸性与致癌性。
产品编号: MS-G65408 纯度: 99.92% CAS No.: 303-47-9 分子式: C20H18ClNO6 分子量: 403.81
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Ochratoxin A (Phe-OTA) 是一种口服有效的、可穿透血脑屏障的食源性真菌毒素,是曲霉属 (Aspergillus) 和青霉属 (Penicillium) 真菌的次生代谢产物,属于 2B 类致癌物,其通过诱导氧化应激、抑制线粒体呼吸、造成氧化性 DNA 损伤、破坏 PPAR-γ-CD36 轴、诱导免疫抑制、介导线粒体依赖性凋亡 (apoptosis)、抑制谷氨酸吸收、引发脱髓鞘病变与神经炎症、导致 DNA 低甲基化及抑制细胞增殖等途径,可诱发肾毒性、肝毒性、免疫毒性、神经毒性,并具有致突变性、致畸性与致癌性。

生物实验数据

生物活性 Ochratoxin A (Phe-OTA) is an orally effective, blood-brain barrier-penetrating foodborne mycotoxin, a secondary metabolite of Aspergillus and Penicillium fungi, and a class 2B carcinogen that induces oxidative stress, inhibits mitochondrial respiration, causes oxidative DNA damage, disrupts the PPAR-γ-CD36 axis, induces immunosuppression, mediates mitochondrial-dependent apoptosis, inhibits glutamate uptake, triggers demyelinating lesions and neuroinflammation, leads to DNA hypomethylation, and inhibits cell proliferation, thereby inducing nephrotoxicity, hepatotoxicity, immunotoxicity, and neurotoxicity, and also exhibiting mutagenicity, teratogenicity, and carcinogenicity.
体外研究
(In Vitro)

Ochratoxin A (1-100 μM; 24 h) 可降低 SH-SY5Y 和 HT22 细胞的活力并增加 RONS 生成,在 HT22 细胞中诱导线粒体依赖性凋亡并改变蛋白质组表达,但对 SH-SY5Y 细胞的蛋白质组无显著影响。
Ochratoxin A (1 nM-100 μM; 24-72 h) 可抑制大鼠皮质星形胶质细胞的细胞外谷氨酸摄取,其 IC50 值分别为 1.3 μM 和 10.1 μM,作用机制为降低 GLAST 和 GLT-1 的细胞表面表达,而不改变转运体的总水平。
Ochratoxin A (2 nM-10 nM; 2-10 days) 可在大鼠三维全脑聚集培养物中诱导神经炎症、脱髓鞘以及神经元、少突胶质细胞和星形胶质细胞功能异常,其作用机制可能与 Sonic hedgehog 信号通路受损有关。
Ochratoxin A (1 nM-1 μM; 1-2 days) 会诱导 SH-SY5Y 细胞产生细胞毒性,并改变神经元维持基因的表达;而与人类每日食物摄入量相当的剂量 (2 fM, 20 fM; 11 days) 处理 11 天后,对基因表达无影响。
Ochratoxin A (10 nM, 20 nM; 24 h, 48 h) 可通过改变胶质细胞和炎症基因的表达,破坏无血清聚集大鼠脑细胞培养物中星形胶质细胞的细胞骨架完整性及神经保护性胶质反应模式。
Ochratoxin A (10 nM) 可通过破坏 Sonic hedgehog 信号通路,损伤成熟大鼠胚胎端脑三维聚集培养物中的 DNA 合成并改变发育及细胞周期相关基因的表达,但对未成熟培养物无影响。
Ochratoxin A (2.5-30 μM; 48 h) 可在 SHSY5Y 和 HT22 细胞中诱导氧化性 DNA 损伤及全基因组 DNA 低甲基化,在 15-30 μM 浓度下会导致 HT22 细胞出现染色体不稳定性,且大部分效应随时间推移具有可逆性。
Ochratoxin A (0.5-2 μM; 48 h) 可通过细胞周期阻滞、钙超载及促凋亡信号通路的激活,抑制 NHA-SV40LT 细胞的增殖并诱导其发生线粒体依赖性凋亡。
Ochratoxin A (31.25-2000 nM; 24 h) 可通过上调促炎细胞因子及介质的表达,在永生化小鼠小胶质细胞 BV-2 中诱导促炎反应。

Cell Viability Assay

Cell Line: human dopamine-producing neuroblastoma SH-SY5Y cells, mouse hippocampal HT22 cells
Concentration: 1, 10, 100 μM
Incubation Time: 24 h
Result: Significantly decreased cell viability in both cell lines.
Increased RONS production in both cell lines.
Induced mitochondria-dependent apoptosis (caspase-3 activation and p53 phosphorylation) only in HT22 cells.
Down-regulated 22 protein spots and up-regulated 17 protein spots in HT22 cells, including ornithine aminotransferase, nucleophosmin 1, valosin containing protein, peroxiredoxin 6, prohibitin, prolyl 4-hydroxylase, Atp5b protein, and eukaryotic translation elongation factor 1 delta isoform.
Caused no significant proteome changes in SH-SY5Y cells.

Real Time qPCR

Cell Line: human neuroblastoma SH-SY5Y cells
Concentration: 2 fM, 20 fM; 1 nM, 10 nM, 50 nM, 0.1 μM, 0.5 μM, 1 μM
Incubation Time: 11 days (2 fM, 20 fM); 1 day, 2 days (1 nM, 10 nM, 50 nM, 0.1 μM, 0.5 μM, 1 μM)
Result: Did not modify expression of BDNF, MAPT, TPPP, BAX, or P53 at 2 fM and 20 fM for 11 days.
Induced cytotoxicity and neuronal dysfunction at 1 nM to 1 μM.
Decreased BDNF and TPPP expression at 1 μM at 1 day post-treatment but increased them at 2 days.
Significantly decreased MAPT, BAX, and P53 expression at 1 μM at both 1 day and 2 days post-treatment.

Cell Proliferation Assay

Cell Line: normal human astrocyte (NHA-SV40LT) cells
Concentration: 0.5, 1, 2 μM
Incubation Time: 48 h
Result: Caused dose-dependent decreases in cell proliferation.
Induced sub G0/G1 cell cycle arrest via down-regulation of CDK4, CCND1, CCNE1, and MYC.
Increased cytosolic and mitochondrial calcium levels.
Activated AKT, ERK1/2, and JNK signaling.
Induced mitochondrial membrane potential loss.
Up-regulated pro-apoptotic genes P53 and BAX, as well as MMP2 and PLAUR.

Real Time qPCR

Cell Line: immortalized mouse microglial BV-2 cells
Concentration: 31.25, 62.5, 125, 250, 500, 1000, 2000 nM
Incubation Time: 24 h
Result: Significantly increased mRNA expression of IL-6, TNF-α, IL-1β, and iNOS.
Elevated NO and IL-6 concentrations in culture media.
体内研究
(In Vivo)

Ochratoxin A 可通过降低成熟 CD4+和 CD8+ T 细胞比例、抑制抗体产生诱导雌性 BALB/C 小鼠产生免疫抑制,而产后短期暴露则会刺激免疫应答。
Ochratoxin A 可诱导大鼠发生氧化应激介导的肾毒性,而线粒体重组含锰超氧化物歧化酶可缓解该毒性。
Ochratoxin A 可诱导近端肾小管脂质过氧化,进而导致猪患肾癌。
Ochratoxin A 可诱导鸭肝脏氧化损伤及脂质代谢功能紊乱,姜黄素可缓解其毒性。
Ochratoxin A (1.38-5.53 mg/kg;腹腔注射;单次给药) 短期暴露会导致成年斑马鱼出现运动障碍,同时伴随脑部的适应性抗氧化反应。
Ochratoxin A (0.25-0.5 µM;水体暴露;受精后 6-72 h) 在斑马鱼早期发育阶段暴露会引发剂量依赖性脑出血及脑血管/脑室缺陷。
Ochratoxin A (3.5-6 mg/kg;腹腔注射;单次给药) 急性暴露会增加小鼠脑区的氧化应激水平、耗竭纹状体多巴胺,并抑制氧化 DNA 修复,但不会诱导直接的神经元细胞死亡。
Ochratoxin A (3.0 ppm;日粮给药;妊娠第 6 天至出生后第 77 天) 的发育暴露会导致雄性大鼠后代海马神经发生短暂减少及神经化学改变,出生后第 77 天时无持续性影响。
Ochratoxin A (3.5 mg/kg;腹腔注射;3 天内累计给药 1 至 6 次) 急性暴露可呈剂量依赖性地损伤成年雄性小鼠海马齿状回中的星形胶质细胞结构并降低神经元存活率。
Ochratoxin A (3.5 mg/kg;腹腔注射;3 天内累计给药 1、2、3 或 6 次) 急性暴露可呈剂量依赖性降低成年雄性 Mus musculus脑室下区的细胞增殖水平、神经胶质细胞数量及神经元分化能力。
Ochratoxin A (0.21-0.5 mg/kg bw;口服;每日;28 天) 的亚慢性暴露会在 Balb/c 小鼠中诱导出持续性帕金森病样病理特征及精细运动功能损伤。
Ochratoxin A (10 mg/kg;口服;每日;连续 28 天) 亚慢性口服暴露会诱导大鼠脑组织产生氧化应激,但不会造成组织病理学损伤。
Ochratoxin A (289 µg/kg;口服;每日;4 周) 亚慢性口服暴露可下调大鼠海马 NMDA 受体亚基 NR2A 和 NR2B。
Ochratoxin A (3.5 mg/kg;腹腔注射;每日;连续 3 天) 急性暴露会诱导雄性小鼠出现帕金森样行为、神经递质耗竭、氧化应激及神经元凋亡通路抑制。

Animal Model: Adult zebrafish
Dosage: 1.38 mg/kg; 2.77 mg/kg; 5.53 mg/kg
Administration: i.p.; single dose
Result: Induced locomotor impairment, with decreased mean speed, total distance traveled, and absolute turn angle, plus increased freezing time.
Showed no effect on social interaction.
Increased glutathione reductase, glutathione-S-transferase, and glutathione peroxidase activities in brain tissue.
Decreased non-protein thiols level in brain tissue.
Showed no change in lipid peroxidation level in brain tissue.
Animal Model: wild-type AB strain, double transgenic Tg(fli1a:EGFP; gata1:DsRed) (embryos)
Dosage: 0.25 µM; 0.5 µM
Administration: water exposure; 6-72 h post fertilization
Result: Caused dose-dependent cerebral hemorrhage, most frequent in the hindbrain.
Detected extravasated erythrocytes in hindbrain, midbrain, forebrain, and ventricular cranial interstitial spaces at the 0.5 µM dose.
Impaired early brain ventricle development at the 0.5 µM dose, causing abnormal cavities, reduced tissue mass, and defective hindbrain organization.
Animal Model: Swiss ICR (male)
Dosage: 3.5 mg/kg; up to 6 mg/kg
Administration: i.p.; single dose
Result: Caused a dose-dependent reduction in striatal dopamine content and turnover at doses up to 6 mg/kg.
Significantly decreased tyrosine hydroxylase immunoreactivity in striatal fibers, locus ceruleus cells, and substantia nigra cells at 72 h post-treatment with the 3.5 mg/kg dose.
Increased superoxide dismutase activity, lipid peroxidation level, and oxidative DNA damage in all investigated brain regions (hippocampus, cerebral cortex, cerebellum, midbrain, pons/medulla, caudate/putamen).
Induced transient inhibition of oxidative DNA repair at 6 h post-treatment.
Showed no cell death or changes in dopamine and cyclic AMP regulated phosphoprotein (DARPP32) levels.
Animal Model: Sprague Dawley (male offspring)
Dosage: 0.12 ppm; 0.6 ppm; 3.0 ppm
Administration: dietary; gestation day 6 to postnatal day 77
Result: Significantly decreased hippocampal neurogenesis-related indices in male postnatal day 21 offspring at the 3.0 ppm dose, including reduced type-2 progenitor cells (PAX6+ or TBR2+), decreased hilar GABAergic interneurons (SST+ or CHRNB2+), down-regulated cholinergic signaling, and increased malondialdehyde accumulation in the subgranular zone of the dentate gyrus.
Significantly increased mRNA expression of neurotrophin (Bdnf), serotonergic receptors (Tph2, Htr1a, Htr4), serotonin-synthesizing enzyme, and glutamatergic receptors (Gria1, Gria2, Grin2a) in the dentate gyrus at the 3.0 ppm dose.
Showed no developmental gait abnormalities or brain histopathology at any dose on postnatal day 21 or 77.
Showed no neurochemical changes at postnatal day 77.
Animal Model: C57BL/6 (male)
Dosage: 3.5 mg/kg
Administration: i.p.; 1 to 6 cumulative doses over 3 days
Result: Caused a dose-dependent, significant reduction in astrocyte branch length and number, GFAP cell expression, astrocyte quantity, young neuron count, and mature neuron count in the hippocampal dentate gyrus.
Animal Model: C57BL/6 (adult male)
Dosage: 3.5 mg/kg
Administration: i.p.; 1, 2, 3, or 6 cumulative doses over 3 days
Result: Caused a dose-dependent decrease in cellular proliferation, astrocyte count (reduced GFAP immunostaining), microglia count (reduced Iba1 immunostaining), young neuron count (reduced doublecortin immunostaining), beta III tubulin (TUJ1) cell count, and calretinin+ cell count in the subventricular zone.
Animal Model: Balb/c
Dosage: 0.21 mg/kg bw; 0.5 mg/kg bw
Administration: p.o.; daily; 28 days
Result: Significantly impaired fine motor function (wire hang and negative geotaxis tests) despite no overt clinical toxicity, unchanged body weight, and undetectable ochratoxin A in plasma and brain tissue after the 6-month recovery period.
Induced loss of striatal dopaminergic innervation, dopaminergic cell dysfunction, increased phosphorylated alpha-synuclein levels, and a dose-dependent decrease in lysosome-associated membrane protein type 2 A (LAMP-2A) level in the midbrain.
Showed no effect on hsc70 protein level.
Animal Model: Rats
Dosage: 10 mg/kg
Administration: p.o.; daily; 28 days
Result: Caused a significant decrease in brain glutathione level and superoxide dismutase activity.
Caused significant increases in brain catalase activity, glutathione reductase activity, and malondialdehyde level.
Showed no histopathological brain injury.
Animal Model: Rats
Dosage: 289 µg/kg
Administration: p.o.; daily; 4 weeks
Result: Significantly decreased protein expression levels of hippocampal N-methyl-D-aspartate (NMDA) receptor subunits NR2A and NR2B.
Animal Model: Male mice
Dosage: 3.5 mg/kg
Administration: i.p.; daily; 3 consecutive days
Result: Induced Parkinsonian physiognomies, including impaired performance in spontaneous activity, gait analysis, pole test, and cylinder tests.
Caused significant reductions in whole brain, hippocampus, and striatum levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT), norepinephrine, 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA).
Increased oxidative stress.
Inhibited neuronal apoptosis pathways (PI3K/AkT signaling) and Fork head box (FOXO) transcriptional activity.
Caused brain histopathological injuries.
性状 固体
颜色 White to off-white

化学信息

分子量 403.81
分子式 C20H18ClNO6
CAS No. 303-47-9
别名 赭曲霉毒素 A; Phe-​OTA

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (123.82 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.4764 mL12.3821 mL24.7641 mL61.9103 mL
5 mM0.4953 mL2.4764 mL4.9528 mL12.3821 mL
10 mM0.2476 mL1.2382 mL2.4764 mL6.1910 mL
15 mM0.1651 mL0.8255 mL1.6509 mL4.1274 mL
20 mM0.1238 mL0.6191 mL1.2382 mL3.0955 mL
25 mM0.0991 mL0.4953 mL0.9906 mL2.4764 mL
30 mM0.0825 mL0.4127 mL0.8255 mL2.0637 mL
40 mM0.0619 mL0.3096 mL0.6191 mL1.5478 mL
50 mM0.0495 mL0.2476 mL0.4953 mL1.2382 mL
60 mM0.0413 mL0.2064 mL0.4127 mL1.0318 mL
80 mM0.0310 mL0.1548 mL0.3096 mL0.7739 mL
100 mM0.0248 mL0.1238 mL0.2476 mL0.6191 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础